Recordati investor CVC taps up potential buyers of drugs group, rival says
Adds background and Angelini statement, paragraphs 5-6
By Giancarlo Navach
MILAN, Nov 26 (Reuters) -The main shareholder of Italy's Recordati RECI.MI is in contact with other Italian drugmakers over a possible sale, the chief executive of rival Dompe Farmaceutica told Reuters on Tuesday.
Speculation about the future of Recordati increased over the summer after majority shareholder CVC Capital Partners hired investment banks JP Morgan JPM.N and Goldman Sachs GS.N to explore options for the drugmaker.
"We know there has been contact with other Italian pharmaceuticals groups," Dompe Farmaceutica CEO Sergio Dompe said, adding that his company was not interested in a deal.
"Recordati is a listed company that is doing very well and the main shareholder is doing a very good job. (But) if there are opportunities, the fund will look at them," Dompe added.
Earlier press reports suggested that rival Angelini Pharma was a potential buyer of CVC's 51.8% stake in Recordati.
Angelini declined to comment on Recordati but said in an emailed statement that it "always looks at all market opportunities".
CVC declined to comment and a Recordati representative was not immediately available for comment.
Reporting by Giancarlo Navach
Editing by Cristina Carlevaro and David Goodman
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
